Ensuring patient privacy in data sharing for postapproval research

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1644-1649

  Sarpatwari, Ameet ^a   Kesselheim, Aaron S ^a   Malin, Bradley A ^b   Gagne, Joshua J ^a   Schneeweiss, Sebastian ^a  

^a Division of Pharmacoepidemiology and Pharmacoeconomics   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HEALTH CARE; HUMAN; LAW; MEDICAL INFORMATION; MEDICAL RESEARCH; OBSERVATIONAL STUDY; PATIENT RIGHT; PRIMARY MEDICAL CARE; PRIVACY; PUBLIC HEALTH; SIMULATION; SOCIOECONOMICS; CONFIDENTIALITY; DATA BASE; ETHICS; GOVERNMENT; GOVERNMENT REGULATION; HEALTH INSURANCE; INFORMATION DISSEMINATION; LEGAL ASPECT; METHODOLOGY; STANDARD; UNITED STATES;

CONFIDENTIALITY; DATABASES AS TOPIC; GOVERNMENT REGULATION; HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT; HUMANS; INFORMATION DISSEMINATION; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;

EID: 84908147009     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb1405487     Document Type: Article

References (32)

1. Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health (Larchmt) 2011;20:315-20.
2. Zulman DM, Sussman JB, Chen X, Cigolle CT, Blaum CS, Hayward RA. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011;26:783-90.
3. Darrow JJ. Crowdsourcing clinical trials. Minn Law Rev 2014;98:805-66.
4. Health Insurance Portability and Accounting Act, Pub. L. No. 104-191, 110 Stat. 1936 (Aug. 21, 1996).
5. Health Information Technology for Economic and Clinical Health Act, Title XIII of Division A and Title IV of Division B of the American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123 Stat. 226 (Feb. 17, 2009).
6. Uses and disclosures from for which an authorization or opportunity to agree or object is not required, 45 C.F.R. 164.512(b)(1).
7. New drugs, 21 U.S.C. 355(k)(3)(b).
8. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf 2012;21:Suppl 1:18-22.
9. Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science - big data rendered fit and functional. N Engl J Med 2014;370:2165-7.
10. Evans BJ. Institutional competence to balance privacy and competing values: the forgotten third prong of HIPAA preemption analysis. Univ Cal Davis Law Rev. 2013;46:1175-230.
11. Rosenbaum S, Borzi PC, Burke T, Nath SW. Does HIPAA preemption pose a legal barrier to health information transparency and interoperability? BNA Health Care Policy Rep 2007; 15:1-14.
12. Sun LH. Clinic fined 4.3 million for failing to provide patients' medical records. Washington Post. February 21, 2011 (http://www.washingtonpost.com/wp-dyn/content/article/2011/02/22/AR2011022207094.html).
13. Department of Health and Human Services, Office of Civil Rights. Case examples and resolution agreements (http://www.hhs.gov/ocr/privacy/hipaa/enforcement/examples).
14. Reisz LP. State attorneys general wade further into HIPAA pool. Lexicology. August 7, 2012 (http://www.lexology.com/library/detail.aspx?g=9112198e-20e0-4640-8c36-6925a95c3ac6).
15. Food and Drug Administration. Unique device identification system: final rule. Fed Regist 2013;78:58786-828.
16. U.S. Census Bureau. Geographic terms and concepts - census tracts (http://www.census.gov/geo/reference/gtc/gtc-ct.html).
17. Kamel Boulos MN, Cai Q, Padget JA, Rushton G. Using software agents to preserve individual health data confidentiality in micro-scale geographical analyses. J Biomed Inform 2006;39: 160-70.
18. Glover J, Rosman D, Tennant S. Unpacking analyses relying on area-based data: are the assumptions supportable? Int J Health Geogr 2004;3:30.
19. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008;84:362-9.
20. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8.
21. Candela S, Pergolizzi S, Ragni P, et al. An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. Vaccine 2013;31:1431-7.
22. Funch D, Gydesen H, Tornøe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2014;16:273-5.
23. Burmester GR, Matucci-Cerinic M, Mariette X, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther 2014; 16(1):R24.
24. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-44.
25. Brownstein JS, Green TC, Cassidy TA, Butler SF. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol Drug Saf 2010;19:627-37.
26. Malin B, Benitez K, Masys D. Never too old for anonymity: a statistical standard for demographic data sharing via the HIPAA Privacy Rule. J Am Med Inform Assoc 2011;18:3-10.
27. Benitez K, Malin B. Evaluating re-identification risks with respect to the HIPAA privacy rule. J Am Med Inform Assoc 2010;17:169-77.
28. Department of Health and Human Services, Office of Civil Rights. Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule (http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html).
29. El Emam K, Arbuckle L. Anonymizing health data: case studies and methods to get you started. Sebastopol, CA: O'Reilly Media, 2013.
30. El Emam K, Jonker E, Arbuckle L, Malin B. A systematic review of re-identification attacks on health data. PLoS One 2011; 6(12):e28071.
31. Cohen IG, Amarasingham R, Shah A, Xie B, Lo B. The legal and ethical concerns that rise from using complex predictive analytics in health care. Health Aff (Millwood) 2014;33:1139-47.
32. Encouraging the use of, and rethinking protections for deidentified (and "anonymized") health data. Washington, DC: Center for Democracy & Technology, June 2009 (https://cdt.org/files/pdfs/20090625-deidentify.pdf).